Difference between revisions of "Chromophobe renal cell carcinoma"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
| Line 66: | Line 66: | ||
== Epigenomics (methylation) == | == Epigenomics (methylation) == | ||
| + | Unknown | ||
== Main Pathways Involved == | == Main Pathways Involved == | ||
Revision as of 09:06, 29 July 2016
Contributors
Daynna Wolff PhD FACMG Yajuan Liu, PhD Rajyasree Emmadi, MD Banumathy Gowrishankar, PhD Jane Houldsworth, PhD
Tumor Type
Renal Cell Carcinoma
Tumor Classification
Chromophobe Renal Cell Carcinoma
Description
Chromophobe Renal Cell Carcinoma derives from the intercalated cells of the collecting duct epithelium and accounts for ~5% of renal tumors (Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579).
IHC Markers
Positive: CD10 , CD117, E-cadherin, EMA, CK7, PAX8, PAX2, AMACR.
Negative: vimentin, RCC, CA-IX.
Genomic Gain/Loss/LOH
| Chromosome | Gain/Loss/Amp | Region |
|---|---|---|
| 1 | Loss | Chr1 |
| 2 | Loss | Chr2 |
| 6 | Loss | Chr6 |
| 10 | Loss | Chr10 |
| 13 | Loss | Chr13 |
| 17 | Loss | Chr17 |
| 21 | Loss | Chr21 |
Rearrangements
TERT (upstream) (5p15) (12%)
Mutations (SNV/INDEL)
From Cosmic Mutated in >20%
Mutated in 10-20%
TP53
Mutated in 5-10%
VHL, PTEN
Mutated in 2-5%
KMT2D, KMT2C, TERT, MET, ARID1A, FAAH2, PDHB, PDXDC1, ZNF765
mtDNA
Epigenomics (methylation)
Unknown
Main Pathways Involved
Diagnosis
Prognosis
Therapeutics
Familial Forms
Birt-Hogg-Dube syndrome (BHD): FLCN (17p11.2)